Therapeutic Profile of Human Umbilical Cord Blood Serum and Autologous Serum Therapies in Treatment of Ocular Surface Disorders: A Pilot Study

Kumar, Akhilesh; Chaurasiya, Deepti; Sultan, Shabana; Soni, Deepak; Kubrey, Suraj; Singh, Priti; Verma, Shipra; Mohan, Rajiv R.; Sharma, Bhavana

doi:10.1089/jop.2022.0107

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they induce anti-inflammatory actions. Human umbilical cord serum has a higher level of growth factors than autologous serum, which may provide a more powerful treatment effect and make it suitable for Stevens-Johnson syndrome and ocular chemical injury, besides the previously mentioned disorders that are effective with autologous serum eyedrops [60,61]. Nevertheless, since some reports [62] have shown that autologous serum eye drops did not improve corneal epithelial injury much, its ability to ameliorate epithelial injury may be questionable.…”

Section: Human Umbilical Cord Serum Eye Dropsmentioning

confidence: 99%

Management of Dry Eye Disease in Asia: A Review

Kawahara¹

2023

Preprint

View full text Add to dashboard Cite

Dry eye disease (DED) is a multifactorial disorder in which tear fluid homeostasis is lost, resulting in increased tear film osmolarity and ocular surface irritation. In Asia, the short tear film breakup time type-DED is common, and stabilization of the tear film is the first goal of treatment. Treatment of DED begins with eye drops. Until now, artificial tears and steroid eye drops have been the main treatment for DED. However, artificial tears require frequent administration of eye drops and thus pose adherence problems, while steroids have problems with side effects (cataracts, increased intraocular pressure). This review evaluates the new generation of DED therapies in Asia based on what is known about them and demonstrates that they are more effective for DED than traditional therapies such as artificial tears and steroids. Based on these considerations, it is proposed that the optimal treatment for DED in Asia is the initial application of mucin secretion enhancing eye drops (long-acting diquafosol) and oral supplements, and if additional treatment is needed, cyclosporine eye drops and the adjunctive therapies presented in this review are added.

show abstract

Section: Human Umbilical Cord Serum Eye Dropsmentioning

confidence: 99%

Management of Dry Eye Disease in Asia: A Review

Kawahara¹

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…They also cause anti-inflammatory effects. Human umbilical cord serum has a higher level of growth factors than autologous serum, which may provide a more powerful treatment effect and make it suitable for Stevens-Johnson syndrome and ocular chemical injury, in addition to the previously mentioned disorders that are effective with autologous serum eyedrops [70,71]. Nevertheless, since some reports [72] have shown that autologous serum eye drops did not improve corneal epithelial injury much, its ability to ameliorate epithelial injury may be questionable.…”

Section: Human Umbilical Cord Serum Eye Dropsmentioning

confidence: 99%

Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED

Kawahara

2023

Pharmaceutics

View full text Add to dashboard Cite

Dry eye disease (DED) is a multifactorial disorder in which tear fluid homeostasis is lost, resulting in increased tear film osmolarity and ocular surface irritation. In Asia, the short tear film breakup time-type DED, which has become a global problem in recent years, is common. While the mainstay of DED treatment in the West is the suppression of inflammation, the first goal of treatment is the stabilization of the tear film in Asia. To date, artificial tears and steroid eye drops have been the main treatment for DED. However, artificial tears require frequent administration of eye drops and thus pose adherence problems, while steroids have problems with side-effects (cataracts, increased intraocular pressure). This review evaluates the new generation therapies in Asia based on what is known about them and demonstrates that they are more effective for DED than traditional therapies such as artificial tears and steroids. Based on considerations, it is proposed that the optimal treatment for the short tear film breakup time-type DED is the initial application of mucin-secretion-enhancing eye drops (long-acting diquafosol) and oral supplements; and if additional treatment is needed, cyclosporine eye drops and the adjunctive therapies presented in this review are added.

show abstract

Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study

Ren,

Tian,

Shi

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Objective The cross-sectional study was designed to evaluate the association of ocular surface inflammation with systemic conditions in patients with systemic lupus erythematosus (SLE). Methods The study enrolled 30 SLE patients and 30 controls. Ocular symptoms were evaluated using the Ocular Surface Disease Index (OSDI) questionnaire. Tear samples from all participants were collected for tear multi-cytokine and chemokine concentration analysis. All participants were assessed for dry eye disease (DED), including Schirmer I test, tear break-up time (TBUT), corneal fluorescein staining (CFS), meibomian gland secretion (MGS), lid-parallel conjunctival folds (LIPCOF), corneal clarity, and symblepharon. Besides, all participants were also examined for conjunctival impression cytology to measure the density of conjunctival goblet cells (CGCs). The peripheral blood indicators from SLE patients were also collected to measure the SLE-associated autoantibody specificities and systemic inflammatory indicators. Pearson and Spearman’s analysis were uesd to examine the correlation between tear cytokines, CGCs, DED-related indicators, and systemic conditions. Results The two groups were matched for age and gender in this study. 36.67% of eyes (11 in 30) of SLE patients and 13.33% of eyes (4 in 30) of controls were diagnosed with DED. OSDI scores, abnormal TBUT percentages, CFS percentages, and DED grading were all higher in SLE patients than in control group, while density of CGCs was lower. There were no significant differences in Schirmer I test, MGS, LIPCOF, corneal clarity, and symblepharon between SLE patients and controls. The levels of tear chemokine (C-X-C motif) ligand 11 (CXCL11) and cytokine interleukin-7 (IL-7) in patients with SLE were significantly higher than those in control group. Moreover, among SLE patients, the severity of DED and the level of tear chemokine CXCL11 were significantly positively correlated with SLE-associated autoantibody specificities. Conclusion Dry eye and tear cytokines and chemokines-mediated ocular surface inflammation persist in SLE patients and are associated with systemic conditions. Therefore, it is necessary for patients with SLE to combine systemic and ocular assessments. Supplementary Information The online version contains supplementary material available at 10.1186/s12886-024-03760-8.

show abstract

Therapeutic Profile of Human Umbilical Cord Blood Serum and Autologous Serum Therapies in Treatment of Ocular Surface Disorders: A Pilot Study

Cited by 4 publications

References 17 publications

Management of Dry Eye Disease in Asia: A Review

Management of Dry Eye Disease in Asia: A Review

Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED

Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study

Contact Info

Product

Resources

About